Development of Novel ACK1/TNK2 Inhibitors Using a Fragment-Based Approach-Reference-Cited by-同舟云学术

Development of Novel ACK1/TNK2 Inhibitors Using a Fragment-Based Approach

Published:2015-03-17 Issue:6 Volume:58 Page:2746-2763
ISSN:0022-2623
Container-title:Journal of Medicinal Chemistry
language:en
Short-container-title:J. Med. Chem.

Author:

Lawrence Harshani R.¹,Mahajan Kiran¹,Luo Yunting,Zhang Daniel,Tindall Nathan,Huseyin Miles,Gevariya Harsukh,Kazi Sakib,Ozcan Sevil,Mahajan Nupam P.¹,Lawrence Nicholas J.¹

Affiliation:

1. Department of Oncologic Sciences, University of South Florida, Tampa, Florida 33620, United States

Funder

National Cancer Institute

Congressionally Directed Medical Research Programs

Publisher

American Chemical Society (ACS)

Subject

Drug Discovery,Molecular Medicine

Link

https://pubs.acs.org/doi/pdf/10.1021/jm501929n

Reference42 articles.

1. ACK1 tyrosine kinase: Targeted inhibition to block cancer cell proliferation

2. ACK1/TNK2 tyrosine kinase: molecular signaling and evolving role in cancers

3. Shepherding AKT and androgen receptor by Ack1 tyrosine kinase

4. Activated Cdc42-associated kinase Ack1 promotes prostate cancer progression via androgen receptor tyrosine phosphorylation

5. Ack1-mediated Androgen Receptor Phosphorylation Modulates Radiation Resistance in Castration-resistant Prostate Cancer

Cited by 39 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. ACK1 and BRK non-receptor tyrosine kinase deficiencies are associated with familial systemic lupus and involved in efferocytosis;2024-08-02

2. ACK1 and BRK non-receptor tyrosine kinase deficiencies are associated with familial systemic lupus and involved in efferocytosis;2024-08-02

3. ACK1 and BRK non-receptor tyrosine kinase deficiencies are associated with familial systemic lupus and involved in efferocytosis;2024-03-22

4. ACK1 and BRK non-receptor tyrosine kinase deficiencies are associated with familial systemic lupus and involved in efferocytosis;2024-02-19

5. Research Progress on AKC1 and Its Small Molecule Inhibitors in Tumor Occurrence and Development;Advances in Clinical Medicine;2024